Episode
Episode 69. ASH 2025 Lymphoma Roundup with Dr. Carla Casulo
- Podcast
- Blood Cancer Talks
- Published
- Jan 22, 2026
- Duration seconds
- 2659
- Processing state
not_requested- Canonical source
- https://share.transistor.fm/s/97e98f98
Actions
POST https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-69-ash-2025-lymphoma-roundup-with-dr-carla-casulo/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-69-ash-2025-lymphoma-roundup-with-dr-carla-casulo.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
BloodCancerTalks: ASH 2025 Lymphoma Roundup Guest: Dr. Carla Casulo, Associate Professor, Wilmot Cancer Centre, University of Rochester Abstracts Discussed Follicular Lymphoma EPCORE-FL1 (Falchi) - Epcoritamab plus lenalidomide-rituximab (R2) in relapsed/refractory FL Theme: Bispecific antibody combinations in R/R FL; comparing to other approaches Diffuse Large B-Cell Lymphoma (DLBCL) - Elderly/Unfit Patients MorningSun (Sharman) - Mosunetuzumab monotherapy in patients ≥80 years or chemo-ineligible EPCOR-DLBCL-3 (Vitolo) - Epcoritamab monotherapy in elderly patients R-Pola-Glo - Rituximab-polatuzumab-glofitamab combination in older/frail patients Theme: Single-agent and combination bispecific strategies for elderly and frail DLBCL patients DLBCL - First-Line Treatment SMART STOP (Westin) - Chemotherapy-free approach using lenalidomide, tafasitamab, rituximab, acalabrutinib (ULTRA regimen) FrontMIND - Tafasitamab-lenalidomide added to R-CHOP Theme: Chemotherapy-sparing and chemo-intensification strategies in newly diagnosed DLBCL DLBCL - Relapsed/Refractory DALY 2-EU (Borchmann) - Dual CD19/CD20 CAR-T (zamto-cel) versus R-GemOx in transplant-ineligible patients Theme: Expanding CAR-T eligibility; treatment selection in transplant-ineligible R/R DLBCL Hodgkin Lymphoma SWOG 1826 - 3-year update: Nivolumab-AVD versus brentuximab-AVD HD21 - 5-year update: PET-adapted BrECADD versus BEACOPP Theme: Long-term outcomes and treatment selection in newly diagnosed Hodgkin lymphoma Burkitt Lymphoma ZUMA-25 (Van Dorp) - Brexucabtagene autoleucel (Brexu-cel) in relapsed/refractory Burkitt Theme: CAR-T therapy for the challenging population of R/R Burkitt lymphoma Mantle Cell Lymphoma - First-Line TrAVeRse - Acalabrutinib, venetoclax, rituximab GLOVe - Glofitamab, lenalidomide, veneto…